ArticleEcancermedicalscience2025
Real-world insights on a rare disease: adenoid cystic carcinoma of the breast.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adenoid cystic carcinoma of the breast (ACCB) is a rare histological subtype of breast cancer characterised by unique clinical features and management challenges. ACCB remains poorly understood, with limited data on its epidemiology, treatment outcomes and prognostic factors. This study aimed to elucidate the landscape of ACCB in a real-world context. Methods: A retrospective cohort study was conducted on patients diagnosed with ACCB in a Brazilian cancer center between January 2007 and October 2021. Clinical and pathological data were systematically collected from electronic medical records. Statistical analyses were performed to identify factors associated with prognosis and assess the impact of treatment interventions. Results: Twenty-one female patients with confirmed ACCB were included in the study. The median age at diagnosis was 55.2 years. Most patients had basaloid (38.1%) or classic (19.0%) histological subtypes. Adjuvant radiotherapy was associated with a trend towards better recurrence-free survival among patients with localised disease HR 0.21, CI 95% 0.04-1.06, Conclusion: Given the rarity of ACCB and the absence of a standard management approach, this small study suggests a potential benefit of local therapies in adjuvant and metastatic settings while indicating the limited efficacy of systemic chemotherapy. Personalised treatment strategies tailored to ACCB are essential to optimising patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.